These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2026 related articles for article (PubMed ID: 23700391)

  • 21. Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B.
    Daemen A; Udyavar AR; Sandmann T; Li C; Bosch LJW; O'Gorman W; Li Y; Au-Yeung A; Takahashi C; Kabbarah O; Bourgon R; Hegde P; Bais C; Das Thakur M
    PLoS One; 2021; 16(12):e0262198. PubMed ID: 34972191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort.
    Nsengimana J; Laye J; Filia A; Walker C; Jewell R; Van den Oord JJ; Wolter P; Patel P; Sucker A; Schadendorf D; Jönsson GB; Bishop DT; Newton-Bishop J
    Oncotarget; 2015 May; 6(13):11683-93. PubMed ID: 25871393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer.
    Low YS; Blöcker C; McPherson JR; Tang SA; Cheng YY; Wong JYS; Chua C; Lim TKH; Tang CL; Chew MH; Tan P; Tan IB; Rozen SG; Cheah PY
    Cancer Lett; 2017 Sep; 403():13-20. PubMed ID: 28624625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer.
    Maak M; Simon I; Nitsche U; Roepman P; Snel M; Glas AM; Schuster T; Keller G; Zeestraten E; Goossens I; Janssen KP; Friess H; Rosenberg R
    Ann Surg; 2013 Jun; 257(6):1053-8. PubMed ID: 23295318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer.
    Bobowicz M; Skrzypski M; Czapiewski P; Marczyk M; Maciejewska A; Jankowski M; Szulgo-Paczkowska A; Zegarski W; Pawłowski R; Polańska J; Biernat W; Jaśkiewicz J; Jassem J
    Clin Exp Metastasis; 2016 Dec; 33(8):765-773. PubMed ID: 27485175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic implications of hMLH1 and p53 immunohistochemical status in right-sided colon cancer.
    Smyth EF; Sharma A; Sivarajasingham N; Hartley J; Monson JR; Cawkwell L
    Dis Colon Rectum; 2004 Dec; 47(12):2086-91; discussion 2091-2. PubMed ID: 15657659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinically applicable 53-Gene prognostic assay predicts chemotherapy benefit in gastric cancer: A multicenter study.
    Zhu L; Wang H; Jiang C; Li W; Zhai S; Cai X; Wang X; Liao L; Tao F; Jin D; Chen G; Xia Y; Mao JH; Li B; Wang P; Hang B
    EBioMedicine; 2020 Nov; 61():103023. PubMed ID: 33069062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Independent prognostic genes and mechanism investigation for colon cancer.
    Li C; Shen Z; Zhou Y; Yu W
    Biol Res; 2018 Apr; 51(1):10. PubMed ID: 29653552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
    Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
    Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
    Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prognostic 4-gene expression signature for squamous cell lung carcinoma.
    Li J; Wang J; Chen Y; Yang L; Chen S
    J Cell Physiol; 2017 Dec; 232(12):3702-3713. PubMed ID: 28160492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
    Di Narzo AF; Tejpar S; Rossi S; Yan P; Popovici V; Wirapati P; Budinska E; Xie T; Estrella H; Pavlicek A; Mao M; Martin E; Scott W; Bosman FT; Roth A; Delorenzi M
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25246611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
    Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
    World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis.
    Schwede M; Spentzos D; Bentink S; Hofmann O; Haibe-Kains B; Harrington D; Quackenbush J; Culhane AC
    PLoS One; 2013; 8(3):e57799. PubMed ID: 23536770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 102.